Cannabidiol (prescription) and Ramelteon interaction
Cannabidiol (prescription) and Ramelteon: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Ramelteon (Rozerem) label · effective 2026-04-15
Fluvoxamine (strong CYP1A2 inhibitor): Increases AUC for ramelteon and should not be used in combination.
The use of alcohol and other CNS depressants may increase the risk of such behaviors.
Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution.
Effects of Other Drugs on ROZEREM Fluvoxamine (strong CYP1A2 inhibitor) AUC 0-inf for ramelteon increased approximately 190-fold, and the C max increased approximately 70-fold upon coadministration of fluvoxamine and ROZEREM, compared to ROZEREM administered alone.
ROZEREM should be administered with caution to patients taking less strong CYP1A2 inhibitors.
From the Cannabidiol (prescription) (Epidiolex) label · effective 2026-05-29
Other CNS depressants, including alcohol, could potentiate the somnolence and sedation effect of EPIDIOLEX.
CNS Depressants and Alcohol Concomitant use of EPIDIOLEX with other CNS depressants (including alcohol) may increase the risk of sedation and somnolence [see Warnings and Precautions ( 5.2 )] .
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.